semaglutide approved for mash Semaglutide, a GLP-1R agonist, is also effective patients – MedNess Semaglutide in MASH with F2-F3

Usually, obesity is caused by inherited, physiological, and environmental factors, as well as diet, physical activity, and exercise choices

A peptide isolated from the saliva of a poisonous lizard, Gila monster ( Heloderma suspectum ), native to the US and Mexico shares 50% amino acid sequence identity with human GLP-1

Keep in mind: For patients starting GLP-1 therapy, this lack of clarity matters

In a widely cited New England Journal of Medicine trial using once-weekly semaglutide 2.4 mg plus lifestyle intervention in adults with overweight or obesity without diabetes, participants had a substantial and sustained reduction in body weight over 68 weeks

"In this population in particular, CMS is really going to be looking at this pilot program over the next several months to make sure that these medications are improving health outcomes and the overall health of these patients, she said